FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Jitesh Jani

Research Profile

Chemicals & Drugs

Living Beings

Phenomena

Phosphorylation

Procedures

Physiology

Cell Cycle

Anatomy

Disorders

Prostatic Neoplasms

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Jitesh P Jani; Richard S Finn; Mary Campbell; Kevin G Coleman; Richard D Connell; Nicolas Currier; Erling Emerson; Eugenia Floyd; Shawn Harriman; John C Kath; Joel Morris; James D Moyer; Leslie R Pustilnik; Kristina Rafidi; Sherry Ralston; Ann Marie K Rossi; Salome Steyn; Larry Wagner; Steven M Winter; Samit K Bhattacharya
Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
Jean S Beebe; Jitesh P Jani; Elisabeth A Knauth; Peter Goodwin; Carla Higdon; Ann Marie K Rossi; Erling Emerson; Martin Finkelstein; Eugenia Floyd; Shawn Harriman; Jim Atherton; Steve Hillerman; Cathy Soderstrom; Kou Kou; Tom Gant; Mark C Noe; Barb Foster; Farzan Rastinejad; Matthew A Marx; Tracey Schaeffer; Pamela M Whalen; W Gregory Roberts
Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
E Gabriella Barbacci; Leslie R Pustilnik; Ann Marie K Rossi; Erling Emerson; Penny E Miller; Brian P Boscoe; Eric D Cox; Kenneth K Iwata; Jitesh P Jani; Kathleen Provoncha; John C Kath; Zhengyu Liu; James D Moyer
The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Jitesh Jani (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2007: Jitesh P Jani; Richard S Finn; Mary Campbell; Kevin G Coleman; Richard D Connell; Nicolas Currier; Erling Emerson; Eugenia Floyd; Shawn Harriman; John C Kath; Joel Morris; James D Moyer; Leslie R Pustilnik; Kristina Rafidi; Sherry Ralston; Ann Marie K Rossi; Salome Steyn; Larry Wagner; Steven M Winter; Samit K Bhattacharya
Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
Cancer research 2007;67(20):9887-93.
2003: Jean S Beebe; Jitesh P Jani; Elisabeth A Knauth; Peter Goodwin; Carla Higdon; Ann Marie K Rossi; Erling Emerson; Martin Finkelstein; Eugenia Floyd; Shawn Harriman; Jim Atherton; Steve Hillerman; Cathy Soderstrom; Kou Kou; Tom Gant; Mark C Noe; Barb Foster; Farzan Rastinejad; Matthew A Marx; Tracey Schaeffer; Pamela M Whalen; W Gregory Roberts
Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Cancer research 2003;63(21):7301-9.
2003: E Gabriella Barbacci; Leslie R Pustilnik; Ann Marie K Rossi; Erling Emerson; Penny E Miller; Brian P Boscoe; Eric D Cox; Kenneth K Iwata; Jitesh P Jani; Kathleen Provoncha; John C Kath; Zhengyu Liu; James D Moyer
The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.
Cancer research 2003;63(15):4450-9.
1999: D J George; Craig Dionne; Jitesh P Jani; Thelma S Angeles; Chikara Murakata; J Lamb; John T Isaacs
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
Cancer research 1999;59(10):2395-401.
1998: Craig Dionne; Anna Marie Camoratto; Jitesh P Jani; E Emerson; NT Neff; Jeffry L Vaught; Chikara Murakata; D Djakiew; J Lamb; G Steven Bova; D George; John T Isaacs
Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1887-98.
1997: Anna Marie Camoratto; Jitesh P Jani; Thelma S Angeles; Anna C Maroney; C Y Sanders; Chikara Murakata; NT Neff; Jeffry L Vaught; John T Isaacs; Craig Dionne
CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity.
International journal of cancer. Journal international du cancer 1997;72(4):673-9.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.